The case for & against
Bull & Bear analysis
Bearish
VYNE Therapeutics (NASDAQ: VYNE) is a biopharmaceutical company focused on developing innovative therapies for dermatological conditions, primarily targeting acne and rosacea. The company is transitioning from a commercial entity specializing in minocycline-based products to a research and development-centric organization, looking to leverage proprietary technologies to address significant unmet medical needs in immunology and inflammatory diseases. Recent developments include their lead programs, such as VYN-201, aimed at inflammatory and immune-mediated diseases.
Bull says
- ↑Lead program VYN-201 targets immunoinflammatory diseases with upcoming data catalysts.
- ↑Partnership with InfraDerm to develop BET inhibitors expands dermatology pipeline.
- ↑Cash balance of ~$53M funds ops into mid-2022, excluding divestiture proceeds.
- ↑Amzeek and Zilzy Rx volumes grew 10% in Q1, exceeding 100k total scripts.
- ↑Emerging candidate FMX-114 addresses atopic dermatitis, boosting TAM potential.
- ↑Strong earnings momentum and high institutional ownership with low leverage profile.
Bear says
- ↓Revenues flat at $4.3M in Q1–Q2 and $4.1M in Q3 indicate weak sales growth.
- ↓Net loss of $21.3M (−$0.41/sh) in Q3 underscores ongoing losses.
- ↓Dependence on FMX-114 launch; failure in market uptake could derail revenue.
- ↓Limited formulary access and pricing pressures may constrain patient reach and pricing.
- ↓High operating expenses of ~$20M per quarter accelerate cash depletion risk.
- ↓Declining sales growth, high short interest, and low trading liquidity raise volatility risk.
Earnings Call · Q3 2020 · Mgmt. Guidance
Updated 08-05-2026neutral
Transcript signals
Bull points
- We are excited to have launched Zilxy on October 1st, which is our 1.5% minocycline topical foam for the treatment of inflammatory lesions of rosacea in adults.
- we are already seeing excitement from healthcare providers relating to the availability of Zilxy as a new treatment option for patients.
- both weekly and monthly prescriptions have now eclipsed pre-COVID levels for the first time since the shutdown in March, and then we are gaining market share.
Bear points
- Our third quarter 2020 GAAP net loss was $24.7 million, or 15 cents per share. This compares to $23.2 million, or 23 cents per share, for the comparable period in 2019.
- our third quarter 2020 adjusted net loss was $22.1 million, or 13 cents per share.
- our 2020 GAAP net loss for the period was $232.4 million, or $1.99 a share.
Read full transcript analysis ›